Japan Biotech Develops 30-Minute Cure For Africa’s Sleeping Sickness
This article was originally published in PharmAsia News
Japanese biotech aRigen Pharmaceuticals says it has developed a fast-acting drug to treat the sleeping sickness that plagues Africa. The company conducted its research with the University of Tokyo on the fungus-based compound ascofuranone that interferes with an oxygen-supplying enzyme. Tests on mice show the drug kills parasites in 30 minutes, but Phase I human trials have not begun. aRigen plans to license development rights to a foreign company. (Click here for more - a subscription may be required
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?